1. Introduction {#s0005}
===============

Enzyme replacement therapies (ERT) have significantly improved the lifespan and clinical outcomes of patients with lysosomal storage disorders and other inherited disorders, such as Pompe disease. Pompe disease is an autosomal recessive glycogen storage disease characterized by a deficiency in lysosomal acid α-glucosidase (GAA) [@bb0005]. The classic infantile form of Pompe disease (IPD) results from complete or near complete deficiency of GAA leading to a severe clinical phenotype [@bb0010], [@bb0015]. Untreated IPD leads to death by 2 years of age due to cardiorespiratory failure [@bb0020], [@bb0025]. Recombinant human GAA (rhGAA, alglucosidase alfa, Genzyme, Cambridge, MA) was FDA approved in 2006 for the treatment of Pompe disease, and its use in IPD has significantly improved the course of disease [@bb0010], [@bb0015], [@bb0030], [@bb0035], [@bb0040], [@bb0045]. The effectiveness of rhGAA treatment depends on several factors including age, stage of disease at start of treatment, and the development of anti-rhGAA IgG antibodies [@bb0050], [@bb0055].

Anti-rhGAA IgG antibodies develop in 89% of IPD patients treated with rhGAA [@bb0060], with a large majority developing immunological tolerance with continued treatment [@bb0050], [@bb0055]. A subset of IPD patients forms high sustained anti-rhGAA IgG antibody titers (HSAT; defined as ≥ 1:51,200 on two occasions ≥ 6 months from the start of ERT) which have been shown to negatively impact clinical outcomes [@bb0055], [@bb0065]. The majority of patients with HSAT produce no native GAA enzyme and are designated cross-reactive immunological material (CRIM)-negative [@bb0070]. CRIM-positive patients produce low levels of GAA enzyme (either functioning or non-functioning), and while they are expected to form tolerance to rhGAA, a subset of CRIM-positive patients (both infantile and late onset cases) also develops HSAT [@bb0070], [@bb0075].

The elimination of anti-rhGAA IgG antibodies, particularly HSAT, has been challenging. Initial immune suppression strategies (with combinations of rituximab, intravenous immunoglobulin \[IVIG\], plasmapheresis, methotrexate, and cyclophosphamide) have required prolonged use of these agents and have been met with limited to no success in patients with HSAT, suggesting that it is extremely hard to eliminate long-lived plasma cells. Timing of immune tolerance induction (ITI) is thus critical in order to prevent an immune response [@bb0065], [@bb0080]. Prophylactic ITI has therefore been instituted in high-risk CRIM-negative patients, and these regimens have been shown to prevent the development of anti-rhGAA IgG antibodies and achieve immune tolerance [@bb0085]. The failure of ITI with previous regimens, particularly in the setting of HSAT, has been hypothesized to be due to failure to target antibody-secreting plasma cells [@bb0065]. Bortezomib, a proteasome inhibitor that is FDA approved for the treatment of multiple myeloma, depletes plasma cells and may mitigate damage to skeletal muscle [@bb0090], [@bb0095], [@bb0100], [@bb0105]. Based upon these effects, bortezomib was added to an ITI regimen of rituximab, IVIG, and methotrexate and was shown to successfully eliminate HSAT in three IPD patients (two CRIM-positive, one CRIM-negative) who had concomitant improvements in clinical measures [@bb0110].

Herein we present two brothers with IPD treated with ITI --- one with this four drug bortezomib-based ITI regimen in the setting of HSAT and the second as prophylaxis with the three drug ITI regimen (rituximab, methotrexate and IVIG) during initiation of treatment with rhGAA. Differences are highlighted showing the advantages of earlier treatment as well as institution of an ITI regimen in the prophylactic setting in a high-risk infant.

2. Methods {#s0010}
==========

Both patients met criteria for classic IPD per standard criteria [@bb0110] and were CRIM-positive by mutation analysis and Western blot (Patient 1: Integrated Genetics, Westborough, MA; Patient 2: Duke University, Durham, NC). Anti-rhGAA IgG antibody titers were evaluated serially by Genzyme. Analysis of left ventricular mass index (LVMI, in g/m^2^) was performed as previously described [@bb0010]. To monitor B-cell recovery, flow cytometry was used to assess CD19% using standard methods. Both patients were enrolled in this study (\# 00001562) for CRIM determination and longitudinal follow-up which was Institutional Review Board (IRB)-approved through Duke University (LDN6709 Site 206; NCT[01665326](ctgov:01665326){#ir0005}). Written informed consent for ITI was obtained from the patients\' parents for this study in November 2013. Patient 1 (index case) developed HSAT and received a bortezomib-based regimen as outlined in [Fig. 1](#f0005){ref-type="fig"} and based on published case series [@bb0110]. Patient 2 received prophylactic ITI at the time of initiation of treatment with rhGAA as outlined in [Fig. 2](#f0010){ref-type="fig"} and as previously published [@bb0085]. Followup is reported on both patients through December 2014.

3. Results {#s0015}
==========

*Patient 1* was a 10-month-old African American male born full term and diagnosed as a neonate with classic IPD. Shortly after birth, he developed supraventricular tachycardia with Wolff--Parkinson--White syndrome and hypertrophic cardiomyopathy. These findings, in addition to mild macroglossia and hypotonia, prompted evaluation for IPD. Genetic testing demonstrated a missense change in allele 1 (c.2105G \> T) and a nonsense mutation in allele 2 (c.2512C \> T) in the *GAA* gene. Parental testing confirmed that each parent carried one mutation. The missense mutation in allele 1 results in leucine replacing arginine 702 (p.Arg702Leu), a nucleotide change reported previously in only one individual with Pompe disease [@bb0115]. The mutation in allele 2 was predicted to result in a premature stop (p.Gln838X), a nucleotide change not previously reported but predicted to be disease causing. CRIM status was determined as CRIM-positive by Western blot analysis (Integrated Genetics). Treatment with alglucosidase alfa (20 mg/kg every 2 weeks) was initiated at age 23 days with improvement in clinical status, particularly LVMI ([Fig. 1](#f0005){ref-type="fig"}). Swallow study as a neonate demonstrated aspiration, therefore he received feeds via a nasogastric tube.

Seronegative status was confirmed prior to initiation of ERT. After approximately 5 months of ERT, the patient developed detectable anti-rhGAA IgG antibodies, initially at a titer of 1:25,600 ([Fig. 1](#f0005){ref-type="fig"}). He then developed HSAT with titer of 1:102,400 on two occasions with concomitant worsening of clinical status. Treatment with a bortezomib-based ITI was initiated based on published data [@bb0110] around 11 months of age with subsequent decline in antibody titers. Three and a half months into ITI, bortezomib was repeated (due to antibody titer remaining at 1:51,200) resulting in a subsequent decline to 1:1200. CD19^+^ B-cells decreased to \< 1% of total while blood cell (WBC) count approximately 2 months from the start of ITI and remained \< 1% ([Table 1](#t0005){ref-type="table"}). Rituximab was weaned to every 8 weeks beginning approximately 9 months into ITI.

Prior to initiation of ITI, the patient was not requiring respiratory support. He developed respiratory failure requiring invasive ventilation on three occasions, all due to viral respiratory tract infections (with respiratory syncytial virus, rhinovirus, and rhinovirus/adenovirus respectively) and/or aspiration. Infection and/or aspiration in the setting of advanced disease were clinically felt to be the primary trigger for these events. Given that the patient was receiving IVIG and had normal WBC count and absolute neutrophil count throughout his admissions, immune suppression from ITI was clinically felt to have a minor etiologic role. Following the second admission, he was discharged home on BiPAP at night. During the third admission (around age 20 months), a tracheostomy was placed due to repeated failure at extubation. Gastrostomy tube was placed around 19 months of age and ultimately converted to a gastrojejunal tube due to concerns of recurrent aspiration. Both a tracheostomy and a gastrostomy tube were recommended during previous admissions, but the family was unwilling to proceed until the third admission. The delay in these procedures likely contributed to the repeated and prolonged admissions.

The patient had significant decline in his motor development. Following his first admission, the patient was admitted to inpatient rehabilitation for 17 days, during which time he was pulling to stand and sitting independently. These developmental gains coincided with decline in antibody titers. Following his second admission, he was admitted to inpatient rehabilitation for 14 days, during which time he was no longer pulling to stand or sitting. He was able to hold objects in his hands, clap his hands, and place objects in his mouth, and he did have good head control. On most recent assessment by Physical Medicine and Rehabilitation (December 2014), he was unable to hold his head up or bring his hands to his mouth. He was able to hold objects when they were placed in his hand, but otherwise he had little movement of his extremities and no obvious antigravity movements.

*Patient 2* was a 3-week-old African American male born full term who was diagnosed with classic IPD prenatally due to his brother\'s known disease status. Genetic testing was performed on prenatal amniocentesis at 18 weeks and demonstrated a missense change in allele 1 (c.2105G \> T) and a nonsense mutation in allele 2 (c.2512C \> T) in the *GAA* gene (identical to brother\'s testing). The diagnosis was confirmed by blood GAA enzyme level on day of life 2. Based upon his brother\'s disease phenotype with the development of HSAT despite early initiation of ERT, prophylactic ITI with rituximab, methotrexate, and IVIG was initiated at the time of first alglucosidase alfa dose (20 mg/kg every 2 weeks; [Fig. 2](#f0010){ref-type="fig"}). Seronegative status was confirmed prior to the initiation of ERT. The patient seroconverted after two months of alglucosidase alfa with anti-rhGAA IgG antibody titer of 1:100, but antibody levels remained low through continued treatment with maximum level of 1:3200 at 12 months. This was in contrast to the older sibling\'s titer of 1:204,800 at age of 10 months. CD19^+^ B-cells decreased to \< 1% of total WBC three weeks from the start of ITI and normalized by approximately 5 months ([Table 1](#t0005){ref-type="table"}). Antibody titers have remained low ranging from 1:200 to 1:3200 following normalization of B-cell counts. His baseline LVMI was markedly elevated at 252 g/m^2^ prior to initiation of ERT and steadily decreased over time ([Fig. 2](#f0010){ref-type="fig"}). Following the completion of ITI, the LVMI normalized. He has been receiving physical and occupational therapy for mild developmental delays. At 12 months of age, he was sitting independently and standing with support, and at age 18 months, he began walking. He has been tolerating a normal diet by mouth with no clinical concerns for aspiration. His weight has increased from \< 3rd percentile to the 15th percentile, and his height remains at the 15--50th percentile for age. His immunizations were held during ITI, but they were resumed with recovery of B-cell counts and were up-to-date.

4. Discussion {#s0020}
=============

ERTs have significantly improved clinical outcomes and survival in patients with many inherited diseases, but the development of immune responses to ERT can negate these effects. While CRIM-negative IPD patients are most likely to develop HSAT, they can occur in CRIM-positive patients [@bb0070], [@bb0075], [@bb0125]. Patients with IPD who develop HSAT have very poor treatment outcomes, and ITI regimens with rituximab, methotrexate, IVIG and bortezomib have shown success at reducing the antibody titers [@bb0110]. Without the addition of bortezomib, there has been limited to no success in the elimination of HSAT [@bb0055], [@bb0065]. Given the success with the bortezomib-based regimen and the elimination of HSAT in patients with an established immune response, this regimen was initiated in Patient 1 and resulted in a 64-fold decrease in antibody titers [@bb0085], [@bb0110]. This patient received only 2 cycles of bortezomib, showing rapid responsiveness to the high titers with addition of bortezomib, in contrast to prior publications without its use [@bb0065], [@bb0130]. As there is significant concordance in clinical progression in classic IPD [@bb0135], the sibling was treated in the ERT-naïve setting and has continued to have low antibody titers. The two patients presented expand upon the use of a bortezomib-based regimen for HSAT and extend the use of preemptive ITI to a high-risk CRIM-positive patient, the latter of which is no different from the CRIM-negative high-risk setting. The proband developed high antibody titers despite starting ERT early (within the first month of life) further adding to the understanding, especially with newborn screening for Pompe disease on the horizon, that early ERT does not necessarily prevent the development of HSAT.

The three previously reported patients appeared to tolerate the bortezomib-based regimen well with steady clinical improvements correlating with decline in antibody titers [@bb0110]. Our Patient 1 also did not appear to have adverse events related to ITI, although he had a complicated clinical course felt to be secondary to advanced disease. At the beginning of each admission for respiratory failure, he had at least 1 virus isolated on nasopharyngeal culture, and 2 of 3 admissions were preceded by an event clinically consistent with aspiration. Aspiration was also felt to complicate his respiratory failure during each admission. His need for respiratory support appeared to escalate between admissions coinciding with continued disease progression in the setting of HSAT. Tracheostomy was discussed during each admission and gastrostomy tube during the latter two admissions, but the family preferred to continue to monitor him closely without these procedures. Delay in tracheostomy and gastrostomy tube placement may have contributed to recurrent aspiration events and admissions for respiratory failure. This highlights the importance of supportive care in these complicated patients.

While successful ITI using a bortezomib-based regimen was initiated after the development of HSAT in Patient 1, this case highlights several key observations: 1) the development of HSAT even when ERT is initiated early (in this case by age 26 days), 2) the challenges in abrogating antibody titers in the entrenched setting, and 3) the inability to completely recover from possibly irreversible muscle damage when titers are high, rendering ERT essentially ineffective. Regarding the latter point, as antibody titers take weeks to decline to clinically insignificant levels and continued accumulation of glycogen furthers muscle damage, enzyme is less likely to have an effect during this period of HSAT and disease continues to progress. These patients are also at high-risk for aspiration events and typically sensitive to minor viral respiratory infections, as evidenced by our patient\'s clinical course. While the ITI regimen used is immune suppressive, this was felt to be a minor trigger for respiratory failure in our patient relative to his advanced IPD.

Comparable to that reported in high-risk CRIM negative patients, Patient 2 received a short course of three drug ITI beginning 1 day prior to the initiation of ERT at age 21 days (which is similar to the proband) [@bb0085]. There is little variability in the clinical course of IPD (in contrast to late onset disease) and significant concordance in clinical phenotype has been demonstrated between siblings (R = 0.6) [@bb0135]. Thus, it is very likely that this patient would have developed HSAT if not treated preemptively with ITI, and while the role of other minor factors in his favorable outcome cannot be excluded (such as favorable genetic polymorphisms), such factors are unlikely to have contributed significantly. The advantages of preemptive ITI are highlighted in this patient, including exposure to fewer ITI drugs, shorter duration of therapy, and improved clinical outcome by preventing prolonged exposure to HSAT. While both patients began ERT early in life, they have had significant differences in outcome related to the development (or prevention) of HSAT.

Precious time is wasted in a rapidly progressive disorder such as IPD. In patients at high-risk for developing HSAT, including CRIM-negative patients and affected siblings of CRIM-positive patients with HSAT, short course ITI with rituximab, IVIG and methotrexate can prevent the development of HSAT and improve clinical outcomes. In patients who have already developed HSAT, a bortezomib-based ITI can successfully and rapidly decrease antibody levels to a clinically insignificant level compared to regimens that do not target plasma cells. Similar to our previous report, this regimen was overall well tolerated with adverse events felt primarily to be due to advanced disease and not to the ITI regimen. ITI should be initiated as early as possible, as clinical response to ERT is minimal with persistent HSAT. It is critical, therefore, that we continue to find ways to predict which patients are at high-risk for HSAT (aside from CRIM status) or treat all cases with a regimen that is safe and well tolerated so that preemptive ITI can be initiated in these patients to improve clinical outcomes.
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![Bortezomib-based immune tolerance induction (ITI) strategy in Patient 1 with high-sustained antibody titers (HSAT). Patient 1 developed HSAT (1:102,400) approximately 8 months into treatment with alglucosidase alfa (20 mg/kg every 2 weeks) which coincided with slight worsening of left ventricular mass index (LVMI; g/m^2^ with upper normal limit of LVMI designated as 64 g/m^2^ per published reports [@bb0120]) and worsening of clinical status. A bortezomib-based four drug ITI strategy was initiated at approximately 11 months of age with concomitant decline in antibody titers from peak of 1:204,800 (prior to start of ITI) to 1:51,200. A second course of bortezomib was repeated at that time with subsequent decline of antibody level to 1:3200. Decrease in LVMI corresponded with decrease in antibody level.](gr1){#f0005}

![Prophylactic immune tolerance induction (ITI) in Patient 2. Patient 2 received a five week course of prophylactic ITI with rituximab, IVIG and methotrexate which was initiated prior to first dose of alglucosidase alfa (20 mg/kg every 2 weeks). Left ventricular mass index (LVMI; g/m^2^ with upper normal limit of LVMI designated as 64 g/m^2^ per published reports [@bb0120]) peaked prior to start of enzyme replacement therapy (ERT) with subsequent decline. Antibody titer remained low during and following ITI on continued ERT.](gr2){#f0010}

###### 

Effect of ITI on percentage and absolute number of CD19^+^ B lymphocytes.

  Weeks on ERT   Patient 1   Patient 2          
  -------------- ----------- ----------- ------ ------
  0              38          1524        32     928
  3              --          --          \< 1   3
  7              --          --          \< 1   4
  10             \< 1        \< 1        --     --
  17             \< 1        9           --     --
  20             \< 1        \< 1        --     --
  22             --          --          40     2035
  36             \< 1        1           --     --
  44             \< 1        1           --     --
